Free Newsletter
Merck's Gerberding discusses advantages, challenges of vaccines
Eighteen months ago, Julie Gerberding left her position as CDC director to head up Merck's vaccine unit, which is responsible for making 14 of the 17 vaccines recommended for kids and nine of the 10 shots adults should received. Once an undesirable area of industry, vaccine development has enjoyed an renaissance over the last several years as drugmakers employ new technology to access lucrative markets. In a interview with Xconomy, Gerberding explores the advantages and challenges vaccines present to Big Pharma. Report
More stories about Merck
Comments
Post a comment
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: